Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A Profit Margin

Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A's profit margin stands at 155.13% as of June 2026. That compares with -28.5% in the prior-year period — up 644.2% year over year. That is above the Healthcare sector average of 13.76%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A reported 155.13% in profit margin versus -28.5% a year earlier — a 644.2% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A sits higher the Healthcare benchmark (13.76%) with a profit margin of 155.13%. That is roughly 1027.4% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of 155.13% for Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A's profit margin evolved across reporting periods, while the comparison chart places FBIOP next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.